17.66 0.00 (0.00%)
After hours: 4:45PM EDT
|Bid||17.66 x 3200|
|Ask||17.67 x 1000|
|Day's Range||17.61 - 18.10|
|52 Week Range||8.28 - 25.02|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 29, 2017 - Jun 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.14|
Collaboration between industry-leading supply chain orchestration (SCO) platform and the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities will bring the capabilities to support hundreds of advanced therapy clinical centers, clinical trials and commercially approved products worldwide. SAN FRANCISCO and IRVINE, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Vineti, Inc., and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) announced a commercial partnership designed to extend end-to-end delivery of cell therapies and gene therapies to a growing number of patients as the industry continues to scale. Pairing Vineti’s supply chain orchestration (SCO) platform with Cryoport’s integrated temperature-controlled capabilities and near real-time monitoring will provide an end-to-end solution for advanced therapies, supporting the assurance of improved drug product quality and patient safety. Vineti and Cryoport together seek to leverage both of their commercial and clinical phase experiences and insights from serving biopharma customers.
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
Every investor in Cryoport, Inc. (NASDAQ:CYRX) should be aware of the most powerful shareholder groups. Generally...
If you're interested in Cryoport, Inc. (NASDAQ:CYRX), then you might want to consider its beta (a measure of share...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Cryoport, Inc. (NASDAQ:CYRX) is a small-cap stock with a market capitalization of US$408m. While investors primarily focus on...
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Cryoport, Inc.'s (NASDAQ:CYRX): Cryoport, Inc. provides cryogenic logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The US$351m market-cap companyRead More...
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
If you own shares in Cryoport Inc (NASDAQ:CYRX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
If you want to know who really controls Cryoport Inc (NASDAQ:CYRX), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in bigger Read More...
Be The Match BioTherapies, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations’ efforts to standardize critical elements of the cell therapy supply chain, as well as processes in apheresis and transplant center networks. An important part of the agreement is to integrate Be The Match BioTherapies’ MatchSource® cell therapy supply chain software and Cryoport’s Cryoportal™ Logistics Management Platform.